Insider · CIK 0001442786
Phillip P. Chan
Files at CTSO (Cytosorbents Corp). First filing Jun 15, 2026, latest Sep 16, 2026.
Phillip P. Chan files SEC Form 4 as CEO and director at CTSO (Cytosorbents Corp). Since Jun 15, 2026, Phillip P. Chan has reported 3 open-market buys worth $198k and 0 open-market sells worth $0, the latest filed on Sep 16, 2026.
A track record needs three past buys with six months of prices behind them; Phillip P. Chan has 0, so none is measured yet.
The newest scored trade: bought $23k of CTSO on Sep 15, 2026, filed Sep 16, 2026, scored 45 (moderate). In the last 12 months: 3 buys worth $198k and 0 sells worth $0.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
CTSO: Cytosorbents Corp
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 45Moderate | Cytosorbents Corp | $23k 3,774 shares | +4% | - | |
| 51Moderate | Cytosorbents Corp | $70k 200,000 shares | +11% | - | |
| 64Notable | Cytosorbents Corp | $105k 261,469 shares | +18% | +3% from low-69% from high |
Transactions
Every row this insider has filed, 13 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 15, 2026 | CTSO Cytosorbents Corp | POpen-market purchase Common Stock | +3,774 | $6.00 | $23k | 100,996 | 27 d ago |
| Sep 4, 2026 | CTSO Cytosorbents Corp | POpen-market purchase Common Stock | +200,000 | $0.35 | $70k | 1,944,432 | 34 d ago |
| Jun 12, 2026 | CTSO Cytosorbents Corp | POpen-market purchase Common Stock | +251,136 | $0.40 | $100k | 1,734,099 | Jun 15, 2026 |
| Jun 15, 2026 | CTSO Cytosorbents Corp | POpen-market purchase Common Stock | +10,333 | $0.43 | $4,443 | 1,744,432 | Jun 15, 2026 |
| Nov 18, 2025 | CTSO Cytosorbents Corp | AGrant or award Common Stock | +100,000 | $0.64 | $64k | 1,482,963 | Nov 20, 2025 |
| Aug 8, 2025 | CTSO Cytosorbents Corp | AGrant or award Common Stock | +105,600 | $0.00 | $0 | 1,382,963 | Aug 8, 2025 |
| Aug 8, 2025 | CTSO Cytosorbents Corp | AGrant or award Stock Option (Right to Buy)derivative | +136,400 | $0.00 | $0 | 136,400 | Aug 8, 2025 |
| Feb 24, 2025 | CTSO Cytosorbents Corp | OOut-of-the-money exercise Common Stock | +34,168 | $1.13 | $39k | 1,277,363 | Feb 26, 2025 |
| Feb 24, 2025 | CTSO Cytosorbents Corp | OOut-of-the-money exercise Series A Right Warrants (right to buy)derivative | -34,168 | $1.13 | $39k | 0 | Feb 26, 2025 |
| Jan 17, 2025 | CTSO Cytosorbents Corp | XIn-the-money exercise Common Stock | +90,832 | $1.00 | $91k | 1,243,195 | Jan 22, 2025 |
| Jan 17, 2025 | CTSO Cytosorbents Corp | XIn-the-money exercise Subscription Rights (right to buy)derivative | -90,832 | $0.00 | $0 | 0 | Jan 22, 2025 |
| Jan 17, 2025 | CTSO Cytosorbents Corp | JOther Series A Right Warrantsderivative | +90,832 | - | - | 90,832 | Jan 22, 2025 |
| Jan 17, 2025 | CTSO Cytosorbents Corp | JOther Series B Right Warrantsderivative | +90,832 | - | - | 90,832 | Jan 22, 2025 |
Questions about Phillip P. Chan
Answered from the filings on this page, as of the latest one.
Is Phillip P. Chan buying or selling?
In the last 12 months Phillip P. Chan reported 3 open-market buys worth $198k and 0 open-market sells worth $0 on SEC Form 4; the latest was bought $23k of CTSO on Sep 15, 2026. Grants, option exercises and tax withholding are not counted.
How did Phillip P. Chan's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Phillip P. Chan has 0.
Where does Phillip P. Chan file Form 4?
Phillip P. Chan has filed Form 4 at CTSO (Cytosorbents Corp) as Chief Executive Officer. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.